Mothers and babies can’t wait: A call for action to end mother-to-child transmission of hepatitis B

White Paper

As the World Health Organization (WHO) works toward its goal to eliminate hepatitis B by 2030, the quest to halt hepatitis B mother-to-child transmission has never been more urgent.

Many of the key issues brought into focus over recent years have combined to delay progress of the prevention of mother-to-child transmission (PMTCT) of hepatitis B. Such issues include racial inequality, discrimination against women, and gross inequalities of healthcare access across the globe.

If we are to reach the 2030 hepatitis B elimination goals, we must address the systemic barriers to PMTCT around the world. Caring for women means providing antenatal care, sexual and reproductive health promotion, and access to essential and lifesaving care. Providing this to mothers, their new-borns and their children is vital for ensuring that hepatitis B is adequately addressed.

The triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B is an effort by WHO to encourage integrated care, and a commitment from countries to address all three diseases. As a global community, it is an opportunity for us to work together, strategically and cooperatively, to alter the lives of poor and underserved women and children within our global society.

Today, 26 July, we haved launched our white paper, outlining the context and human impact of mother-to-child transmission. The white paper makes recommendations, which, when carried out in addition to established guidelines, will ensure that PMTCT services are equitable, accessible, and available to all who need them.

 

This report was supported by Kedrion Biopharma, with an unrestricted educational grant.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close